证券代码：603669 证券简称：灵康药业 公告编号：2025-050 灵康药业集团股份有限公司 关于董事会提议向下修正"灵康转债"转股价格的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 7 月 14 日，灵康药业集团股份有限公司（以下简称"灵康 药业"或"公司"）股价已出现连续三十个交易日中至少有十五个交易日的收盘 价低于当期转股价格的 85%之情形，已触发"灵康转债"的转股价格向下修正条 款。 经公司第四届董事会第三十三次会议审议通过，公司董事会提议向下修 正"灵康转债"的转股价格。 本次向下修正"灵康转债"转股价格尚需提交公司股东大会审议。 一、可转换公司债券的基本情况 （一）经中国证券监督管理委员会证监许可[2020]2640 号文核准，灵康药 业集团股份有限公司（以下简称"灵康药业"或"本公司"）于 2020 年 12 月 1 日公开发行了 525 万张可转换公司债券，每张面值 100 元，发行总额为 525,000,000 元，期限 6 年。 （二）经上海证券交易 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-051 灵康药业集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 30 日 14 点 30 分 召开地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 股东大会召开日期：2025年7月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 30 日 至2025 年 7 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投 ...

[Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss for H1 2025, with attributable net profit between -39.5 million CNY and -35.0 million CNY, and operating revenue from 160 million CNY to 200 million CNY Estimated Financial Performance for H1 2025 | Metric | Estimated Amount (million CNY) | | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | -39.5 to -35.0 | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items)** | -48.5 to -44.0 | | **Operating Revenue** | 160 to 200 | | **Operating Revenue (After Deductions)** | 153.4 to 193.4 | - The performance forecast data for this period has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance Comparison](index=1&type=section&id=Item%202.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) Compared to the same period in 2024, the company's estimated net loss for H1 2025 has narrowed, with 2024 H1 net profit attributable to shareholders at -40.40 million CNY and non-recurring adjusted net profit at -54.42 million CNY Comparative Performance: H1 2025 Forecast vs. H1 2024 Actual | Metric | 2025 H1 Forecast (million CNY) | 2024 H1 Actual (million CNY) | | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | -39.5 to -35.0 | -40.40 | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items)** | -48.5 to -44.0 | -54.42 | - Earnings per share for the same period last year was **-0.06 CNY**[6](index=6&type=chunk) [Reasons for Forecasted Loss and Countermeasures](index=2&type=section&id=Item%203.%20Primary%20Reasons%20for%20Current%20Period%20Forecasted%20Loss) The primary reason for the forecasted loss is insufficient sales gross profit to cover period expenses; the company is implementing strategies including promoting centralized procurement products, leveraging channel advantages for non-centralized procurement products, and expanding pharmaceutical distribution business - The primary reason for the current period's loss is that **sales gross profit cannot cover period expenses**[7](index=7&type=chunk) - Company countermeasures include: - Increasing promotion efforts for products winning centralized procurement bids - Leveraging channel advantages for market promotion of non-centralized procurement products - Expanding pharmaceutical distribution business to enhance company scale and strength[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=Item%204.%20Risk%20Warning) The company explicitly states that the performance forecast data is a preliminary internal calculation and has not been audited by a certified public accountant, thus the final results may differ - This performance forecast represents preliminary calculations by the company's finance department based on professional judgment and has not yet been audited by a certified public accountant[8](index=8&type=chunk) - The company believes there are no significant uncertainties that could affect the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanations](index=2&type=section&id=Item%205.%20Other%20Explanations) The company advises investors that the disclosed data is preliminary, and the final accurate financial figures will be based on the officially released 2025 semi-annual report, urging caution regarding investment risks - The forecast data provided above is preliminary, and the final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)

证券代码：603669 证券简称：灵康药业 公告编号：2025-049 灵康药业集团股份有限公司 第四届董事会第三十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 1、审议通过了《关于向下修正"灵康转债"转股价格的议案》 灵康药业集团股份有限公司（以下简称"公司"）第四届董事会第三十三次 会议通知于 2025 年 7 月 11 日以电话、电子邮件等形式发出，会议于 2025 年 7 月 14 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由董事 长陶灵萍召集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公司监事、高级管理人员列席了会议。本次会议的召集、召开和表决程序符 合有关法律、法规和《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 灵康药业集团股份有限公司董事会 2025 年 7 月 15 日 2 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的公告。 1 特此公告。 具体内容详见同日披露于上海 ...

截至7月7日收盘，CRO概念下跌1.07%，位居概念板块跌幅榜前列，板块内，汇宇制药、*ST双成、睿 智医药等跌幅居前，股价上涨的有15只，涨幅居前的有诺思格、昭衍新药、翰宇药业等，分别上涨 3.03%、2.24%、2.11%。 | 002675 | 东诚药业 | -3.15 | 2.11 | -1460.10 | | --- | --- | --- | --- | --- | | 002821 | 凯莱英 | -2.94 | 1.10 | -1440.10 | | 688117 | 圣诺生物 | -0.77 | 7.83 | -1379.21 | | 603229 | 奥翔药业 | -2.05 | 1.37 | -1331.54 | | 300261 | 雅本化学 | -0.14 | 1.47 | -1240.44 | | 300363 | 博腾股份 | -1.98 | 1.86 | -1086.79 | | 301277 | 新天地 | -0.62 | 7.98 | -1072.75 | | 301509 | 金凯生科 | -0.61 | 7.64 | -985.87 | | 603538 | 美诺华 | ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 转股情况："灵康转债"自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间， 转股的金额为 0 元，因转股形成的股份数量为 0 股，占可转债转股前公司已发行 股份总额的 0.0000%。截至 2025 年 6 月 30 日，累计共有人民币 67,196,000 元 "灵康转债"已转换为公司股票，转股数量为 7,804,755 股，占可转债开始转股 前公司已发行股份总额的 1.0940%。 （五）因"灵康转债" 触发《灵康药业集团股份有限公司公开发行可转换 公司债券募集说明书》中约定的回售条款，公司于 2025 年 4 月 1 日至 2025 年 4 月 8 日进行了回售，回售数量为 10 张，回售资金 ...

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-046 | | --- | --- | --- | | 证券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 关于不向下修正"灵康转债"转股价格的公告 2、因公司实施 2021 年年度利润分配方案，自 2022 年 7 月 5 日起，转股价 格调整为 8.51 元/股，具体内容详见《关于权益分派引起的"灵康转债"转股价 格调整的公告》（公告编号：2022-042）。 3、因触发"灵康转债"转股价格修正条款，自 2024 年 7 月 16 日起，转股 价格由 8.51 元/股修正为 8.00 元/股，具体内容详见《关于向下修正"灵康转债" 转股价格暨转股停复牌的公告》（公告编号：2024-053）。 二、关于不向下修正转股价格的具体内容 重要内容提示： 截至 2025 年 6 月 23 日，灵康药业集团股份有限公司（以下简称"灵康 药业"或"本公司"）股价已出现连续三十个交 ...

Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., has maintained its credit rating for both the company and its convertible bonds, indicating stable financial health and outlook [1][2]. Summary by Relevant Sections Company Credit Rating - The company's credit rating remains at "A-" with a stable outlook, consistent with the previous rating [1][2]. - The last rating was conducted by Dongfang Jincheng International Credit Assessment Co., Ltd. on June 18, 2024 [1]. Convertible Bond Rating - The credit rating for the "Lingkang Convertible Bonds" is also maintained at "A-" with a stable outlook, showing no change from the previous assessment [2].

Group 1 - The company, Lingkang Pharmaceutical Group Co., Ltd., has publicly issued A-share convertible bonds with a total amount of RMB 517.78 million, consisting of 5.25 million bonds at a face value of RMB 100 each [1][4][9] - The bonds are convertible into the company's A-shares, with an initial conversion price set at RMB 8.81 per share, and the conversion period is from June 7, 2021, to November 30, 2026 [2][3][4] - The company has established a special account for the raised funds, which will be used for specific investment projects, including the construction of a production base [9][10][15] Group 2 - In 2024, the company reported a revenue of RMB 379.78 million, a 92.95% increase from RMB 196.83 million in 2023, but incurred a net loss of RMB 130.76 million, an improvement from a loss of RMB 151.50 million in the previous year [12][13] - The total assets decreased by 22.73% to RMB 1.26 billion from RMB 1.62 billion in 2023, and the net assets also fell by 17.32% to RMB 769.76 million [12][13] - The company has terminated the "Hainan Lingkang Pharmaceutical Production Base Construction Project (Phase I)" due to significant changes in project feasibility and will retain the remaining raised funds in the special account [14][15] Group 3 - The company has a credit rating of A- for its bonds as of June 2024, with a stable outlook, reflecting a downgrade from AA- in previous years [12][13] - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds, and there have been no violations reported [10][14] - The company has established a management system for the raised funds, ensuring they are used appropriately for the intended projects [10][14]